Drug treatment for mood disorders in pregnancy
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: During the last few years, several researches, often showing contradictory findings, have investigated the safety of psychotropic medications used for treating mood disorders in pregnancy. Hence, the necessity exists to update this information constantly in order to ensure the safest option for the mother-infant pair. RECENT FINDINGS: The risk of fetal anomalies associated with early in-utero exposure to antidepressants seems to be increased after paroxetine and clorimipramine exposure, whereas prenatal exposure to nearly all antidepressants is linked to the potential onset of the Prenatal Antidepressant Exposure Syndrome. As regards classic mood stabilizers, the teratogenic risk historically reported with lithium should probably be softened, whereas valproate is the medication which shows the strongest association with fetal anomalies. An increased risk of autism-spectrum disorders and infant neurodevelopmental delay is also associated with valproate exposure through the placenta. No significant reproductive safety data are available on atypical antipsychotics, although such medications may indirectly increase the rate of fetal malformation by inducing gestational diabetes. SUMMARY: Avoiding the use of clorimipramine, paroxetine, valproate, and atypical antipsychotics during pregnancy is advisable. However, when starting or continuing pharmacological treatment during pregnancy, clinicians should consider not only the intrinsic iatrogenic risk of birth defects or perinatal complications, but also the general safety profile for the expectant mother. Indeed, specific adverse reactions (such as nausea, vomiting, constipation, and excessive weight gain) may aggravate the classic clinical findings of pregnancy, thus indirectly facilitating the occurrence of pregnancy complications and fetal and neonatal problems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Psychotropic medications are typically used adjunctively to manage commonly co-occurring symptoms [10–12], though there is limited support for a psychopharmacologic approach targeting dissociative symptoms specifically [13].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [12]
Citations
Cites
Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn
Chambers, C. D., Hernandez-Diaz, S., Van Marter, L. J., Werler, M. M., Louik, C., Jones, K. L., & Mitchell, A. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052744 · Cited by 880
Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic Drugs
Meador, K. J., Baker, G. A., Browning, N., Clayton-Smith, J., Combs-Cantrell, D. T., Cohen, M., Kalayjian, L. A., Kanner, A., Liporace, J. D., Pennell, P. B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803531 · Cited by 812
Viguera, A. C., Whitfield, T., Baldessarini, R. J., Newport, D. J., Stowe, Z., Reminick, A., Zurick, A., & Cohen, L. S. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06101639 · Cited by 599
Women’s Attitudes, Preferences, and Perceived Barriers to Treatment for Perinatal Depression
Goodman, J. H. (2009) · Birth · doi:10.1111/j.1523-536x.2008.00296.x · Cited by 526
First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects
Louik, C., Lin, A. E., Werler, M. M., Hernández-Díaz, S., & Mitchell, A. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067407 · Cited by 500
Harmonisation in Pharmacovigilance
Edwards, I. R., & Biriell, C. (1994) · Drug Safety · doi:10.2165/00002018-199410020-00001 · Cited by 395
Sanz, E. J., De-las-Cuevas, C., Kiuru, A., Bate, A., & Edwards, R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17865-9 · Cited by 382
Pregnancy Outcome of Women Using Atypical Antipsychotic Drugs: A Prospective Comparative Study
McKenna, K., Koren, G., Tetelbaum, M., Wilton, L., Shakir, S., Diav-Citrin, O., Levinson, A., Zipursky, R. B., & Einarson, A. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0406 · Cited by 312
AUTISM SPECTRUM DISORDERS FOLLOWING IN UTERO EXPOSURE TO ANTIEPILEPTIC DRUGS
Bromley, R. L., Mawer, G., Clayton-Smith, J., & Baker, G. A. (2008) · Neurology · doi:10.1212/01.wnl.0000339399.64213.1a · Cited by 269
Newport, D. J., Calamaras, M. R., DeVane, C. L., Donovan, J., Beach, A. J., Winn, S., Knight, B. T., Gibson, B. B., Viguera, A. C., Owens, M. J., et al. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111886 · Cited by 257
Cited by
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
Perinatal stress, brain inflammation and risk of autism-Review and proposal
Angelidou, A., Asadi, S., Alysandratos, K.-D., Karagkouni, A., Kourembanas, S., & Theoharides, T. C. (2012) · BMC Pediatrics · doi:10.1186/1471-2431-12-89 · Cited by 153
“Moreover, it was recently shown that use of psychotropic medications by the mother, especially in the third trimester of pregnancy, substantially increases the risk of ASD [71].”
Hanley, G. E., & Mintzes, B. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-242 · Cited by 148
“The evidence on safety of use of atypical antipsychotics is sparse but tends to suggest an increased risk of NICU admission among exposed infants; however, the population of antipsychotic users tends to have much higher rates of many adverse conditions, which likely confounds this association [40,41].”
BackgroundPawluski, J. L., Charlier, T. D., Fillet, M., Houbart, V., Crispin, H. T., Steinbusch, H. W. M., & van den Hove, D. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.11.043 · Cited by 106
“One of the most common treatments or maternal depression during pregnancy and postpartum are elective serotonin reuptake inhibitor (SSRI) antidepressant mediations [6,23].”
Background
Metadata
- Authors
- Gentile, S.
- Affiliations
- Azienda Sanitaria Locale Salerno (IT)
- Corresponding author
- Gentile, Salvatore
- ORCID
- Gentile, Salvatore
- Venue
- Current Opinion in Psychiatry
- Published
- 2011-01
- Volume
- 24
- Issue
- 1
- Pages
- 34-40
- ISSN
- 0951-7367 (ISSN-L)
- OpenAlex
- W2019932824
- Cited by
- 60
- References
- 60
- Citations by year
- 2024: 4 · 2023: 2 · 2021: 1 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 6 · 2014: 12 · 2013: 8 · 2012: 7
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- mood disorders in pregnancy, antidepressants, paroxetine, clomipramine, valproic acid, lithium, atypical antipsychotics, fetal malformations, autism spectrum disorder, neurodevelopmental delay, gestational diabetes mellitus, teratogenicity, perinatal complications
- MeSH terms
- Abnormalities, Drug-Induced, Female, Humans, Infant, Newborn, Pregnancy, Prenatal Care, Prenatal Exposure Delayed Effects, Psychotropic Drugs, Risk Assessment, Perinatal Care, Mood Disorders, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug treatment for mood disorders in pregnancy. https://app.cochat.ai/papers/10.1097/yco.0b013e3283413451
- The paper
- Gentile, S. (2011). Drug treatment for mood disorders in pregnancy. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0b013e3283413451
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.